BamSEC and AlphaSense Join Forces
Learn More

Ionis Pharmaceuticals Inc.

NASDAQ: IONS    
Share price (12/20/24): $35.63    
Market cap (12/20/24): $5.626 billion
Search in Documents
Key Exhibits
External Links

Indentures Filter

EX-4.1
from 8-K 115 pages Ionis Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as Trustee Indenture Dated as of June 12, 2023 1.75% Convertible Senior Notes Due 2028
12/34/56
EX-4.11
from 10-K 4 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.1
from 8-K 110 pages Ionis Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee Indenture Dated as of April 12, 2021 0% Convertible Senior Notes Due 2026
12/34/56
EX-4.9
from 10-K 4 pages Description of the Registrant’s Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934
12/34/56
EX-4.1
from 8-K 106 pages Ionis Pharmaceuticals, Inc. and U.S. Bank National Association, as Trustee Indenture Dated as of December 19, 2019 0.125% Convertible Senior Notes Due 2024
12/34/56
EX-4.2
from 10-K 2 pages ISIS Pharmaceuticals, Inc
12/34/56
EX-4.1
from 10-K 9 pages Ionis Code of Ethics and Business Conduct Philosophy of Ionis Code of Ethics and Business Conduct
12/34/56
EX-4.1
from 8-K 105 pages ISIS Pharmaceuticals, Inc. and Wells Fargo Bank, National Association, as Trustee Indenture Dated as of November 17, 2014 1.00% Convertible Senior Notes Due 2021
12/34/56
EX-4.1
from 8-K 104 pages ISIS Pharmaceuticals, Inc. and Wells Fargo Bank, National Association, as Trustee Indenture Dated as of August 13, 2012 2.75% Convertible Senior Notes Due 2019
12/34/56
EX-4.2
from 8-K 25 pages Registration Rights Agreement by and Between ISIS Pharmaceuticals, Inc., as Issuer and Lehman Brothers Inc., as Representative of the Initial Purchasers Dated as of January 23, 2007
12/34/56
EX-4.1
from 8-K 107 pages ISIS Pharmaceuticals, Inc. 25¤8 % Convertible Subordinated Notes Due 2027 Indenture Dated as of January 23, 2007 Wells Fargo Bank, N.A. Trustee
12/34/56
EX-4.20
from S-3 18 pages ISIS Pharmaceuticals, Inc
12/34/56
EX-4.19
from S-3 120 pages ISIS Pharmaceuticals, Inc. and Wells Fargo Bank Minnesota, National Association as Trustee Indenture Dated as of May 1, 2002 $125,000,000 Principal Amount (Plus Over-Allotment Option) 5 ½% Convertible Subordinated Notes Due 2009
12/34/56
EX-4.18
from S-3 21 pages Registration Rights Agreement
12/34/56
EX-4.2
from 8-K ~5 pages Indenture or similar
12/34/56
EX-4.4
from 10-Q/A 1 page Indenture or similar
12/34/56
EX-4.3
from 10-Q/A 1 page Indenture or similar
12/34/56
EX-4.3
from S-3/A ~10 pages Indenture or similar
12/34/56